Literature DB >> 10536041

Lactose-containing starburst dendrimers: influence of dendrimer generation and binding-site orientation of receptors (plant/animal lectins and immunoglobulins) on binding properties.

S André1, P J Ortega, M A Perez, R Roy, H J Gabius.   

Abstract

Starburst glycodendrimers offer the potential to serve as high-affinity ligands for clinically relevant sugar receptors. In order to define areas of application, their binding behavior towards sugar receptors with differential binding-site orientation but identical monosaccharide specificity must be evaluated. Using poly(amidoamine) starburst dendrimers of five generations, which contain the p-isothiocyanato derivative of p-aminophenyl-beta-D-lactoside as ligand group, four different types of galactoside-binding proteins were chosen for this purpose, i.e., the (AB)(2)-toxic agglutinin from mistletoe, a human immunoglobulin G fraction, the homodimeric galectin-1 with its two binding sites at opposite ends of the jelly-roll-motif-harboring protein and monomeric galectin-3. Direct solid-phase assays with surface-immobilized glycodendrimers resulted in obvious affinity enhancements by progressive core branching for the plant agglutinin and less pronounced for the antibody and galectin-1. High density of binding of galectin-3 with modest affinity increases only from the level of the 32-mer onwards points to favorable protein-protein interactions of the monomeric lectin and a spherical display of the end groups without a major share of backfolding. When the inhibitory potency of these probes was evaluated as competitor of receptor binding to an immobilized neoglycoprotein or to asialofetuin, a marked selectivity was detected. The 32- and 64-mers were second to none as inhibitors for the plant agglutinin against both ligand-exposing matrices and for galectin-1 on the matrix with a heterogeneous array of interglycoside distances even on the per-sugar basis. In contrast, a neoglycoprotein with the same end group was superior in the case of the antibody and, less pronounced, monomeric galectin-3. Intimate details of topological binding-site presentation and the ligand display on different generations of core assembly are major operative factors which determine the potential of dendrimers for applications as lectin-targeting device, as attested by these observations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536041     DOI: 10.1093/glycob/9.11.1253

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  17 in total

1.  Lectin-mediated drug targeting: selection of valency, sugar type (Gal/Lac), and spacer length for cluster glycosides as parameters to distinguish ligand binding to C-type asialoglycoprotein receptors and galectins.

Authors:  S André; B Frisch; H Kaltner; D L Desouza; F Schuber; H J Gabius
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

2.  Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review.

Authors:  Jie Liu; Warren D Gray; Michael E Davis; Ying Luo
Journal:  Interface Focus       Date:  2012-03-21       Impact factor: 3.906

Review 3.  Design and creativity in synthesis of multivalent neoglycoconjugates.

Authors:  Yoann M Chabre; René Roy
Journal:  Adv Carbohydr Chem Biochem       Date:  2010       Impact factor: 12.200

4.  Hexaphenylbenzene as a rigid template for the straightforward syntheses of "star-shaped" glycodendrimers.

Authors:  Yoann M Chabre; Patrick P Brisebois; Leïla Abbassi; Sheena C Kerr; John V Fahy; Isabelle Marcotte; René Roy
Journal:  J Org Chem       Date:  2010-12-29       Impact factor: 4.354

5.  Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation.

Authors:  Anna K Michel; Pratima Nangia-Makker; Avraham Raz; Mary J Cloninger
Journal:  Chembiochem       Date:  2014-08-19       Impact factor: 3.164

6.  Improved bioavailability of inhibitors of Trypanosoma cruzi trans-sialidase: PEGylation of lactose analogs with multiarm polyethyleneglycol.

Authors:  M Eugenia Giorgi; Laura Ratier; Rosalía Agusti; Alberto C C Frasch; Rosa M de Lederkremer
Journal:  Glycobiology       Date:  2012-05-30       Impact factor: 4.313

Review 7.  Synthetic glycoconjugates inhibitors of tumor-related galectin-3: an update.

Authors:  Vanessa Leiria Campo; Marcelo Fiori Marchiori; Lílian Cataldi Rodrigues; Marcelo Dias-Baruffi
Journal:  Glycoconj J       Date:  2016-08-15       Impact factor: 2.916

Review 8.  Tumor galectinology: insights into the complex network of a family of endogenous lectins.

Authors:  Harald Lahm; Sabine André; Andreas Hoeflich; Herbert Kaltner; Hans-Christian Siebert; Bernard Sordat; Claus-Wilhelm von der Lieth; Eckhard Wolf; Hans-Joachim Gabius
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

9.  Crystallization and preliminary crystallographic analysis of recombinant human galectin-1.

Authors:  Stacy A Scott; Ken Scott; Helen Blanchard
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-10-24

10.  Multivalent interactions between lectins and supramolecular complexes: Galectin-1 and self-assembled pseudopolyrotaxanes.

Authors:  Jason M Belitsky; Alshakim Nelson; Joseph D Hernandez; Linda G Baum; J Fraser Stoddart
Journal:  Chem Biol       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.